<DOC>
	<DOCNO>NCT00947791</DOCNO>
	<brief_summary>The purpose study determine whether single intravenous administration N-methyl-D-aspartate antagonist safe effective acute treatment bipolar depression .</brief_summary>
	<brief_title>Treatment Study Bipolar Depression</brief_title>
	<detailed_description>Bipolar disorder ( BPD ) common , recurrent , disable medical condition . Although mania define feature BPD , depression represent majority illness burden patient devastate condition . Despite high degree morbidity mortality associate bipolar depression , currently available treatment often inadequate . Recently , single intravenous ( IV ) dose N-methyl-D-aspartate ( NMDA ) glutamate receptor antagonist ketamine demonstrate rapid antidepressant effect severe unipolar depression . Therefore , objective current study investigate safety efficacy single IV dose ketamine treatment-resistant bipolar depression ( TRBD .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1 . Male female patient , 2170 year ; 2 . Primary diagnosis bipolar I II disorder assess SCIDP confirm study psychiatrist ; 3 . Current depressive episode ≥ 8 week duration ; 4 . History failure respond least three ( 3 ) adequate pharmacotherapy trial current depressive episode ( see definition adequate trial ) ; 5 . Subjects must stable dose divalproex ER serum level great 55 mcg/ml prior enrollment ; 6 . Subjects must free psychotropic medication least 2 week ( 4 week fluoxetine ) prior enrollment ( exception divalproex ER ) ; 7 . Subjects must score ≥ 32 IDSC30 Screening Infusion Day # 1 # 2 ; 1 . Women plan become pregnant , pregnant breastfeeding ; 2 . Any unstable medical illness include hepatic , renal , gastroenterologic , respiratory , cardiovascular , endocrinologic , neurologic , immunologic , hematologic disease ; 3 . Clinically significant abnormal finding laboratory parameter , physical examination , ECG ; 4 . Lifetime history schizophrenia , schizoaffective disorder , OCD , mental retardation , pervasive developmental disorder , Tourette 's syndrome ; 5 . Current presence psychotic , mixed manic symptom ; 6 . Lifetime history antidepressantinduced switch manic episode ; 7 . History rapid cycling bipolar subtype ; 8 . Drug alcohol abuse within precede 3 month dependence within precede 5 year ; 9 . Lifetime exposure ketamine phencyclidine ; 10 . Patients judge study investigator high risk suicide .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Treatment-Resistant</keyword>
	<keyword>ketamine</keyword>
	<keyword>antidepressant</keyword>
	<keyword>glutamate</keyword>
</DOC>